SI-BONE Reports 15.2% Revenue Growth to $56M in Q2 2026

SI-BONE, Inc. reported a notable increase in financial performance for the second quarter of 2026, with revenues reaching $56.0 million, a 15.2% increase from $48.6 million in the same period of 2025. For the first half of 2026, total revenue was $108.6 million, up 13.2% from $95.9 million year-over-year. The company’s gross profit also saw an increase, totaling $44.5 million for the quarter and $86.5 million for the six months, reflecting gross margins of 79.5% and 79.6%, respectively. Despite these gains, SI-BONE reported a net loss of $4.1 million for the quarter, an improvement from a loss of $6.2 million in Q2 2025, and a total net loss of $8.4 million for the first half of 2026, down from $12.7 million in the prior year.

The company’s operational metrics indicate a positive trend, with a 14.9% increase in procedure volumes contributing to the revenue growth. The U.S. market accounted for the majority of sales, generating $53.2 million in Q2 2026, while international sales rose by 25.9% to $2.8 million. SI-BONE's sales force has expanded to over 175 team members in the U.S. and 10 direct sales representatives internationally, enhancing its market reach. The company has also focused on increasing physician engagement, with over 150,000 procedures performed using its technologies since commercialization.

In terms of strategic developments, SI-BONE has continued to innovate its product offerings, launching several new implant lines, including the iFuse INTRA Ti in 2026. The company has invested significantly in research and development, spending $9.4 million in the first half of 2026, which represents 8.7% of its revenue. This investment is aimed at addressing unmet clinical needs and expanding its product portfolio, which has been recognized as breakthrough devices by the FDA.

Financially, SI-BONE's total assets increased to $248.8 million as of June 30, 2026, compared to $238.6 million at the end of 2025. The company’s cash and cash equivalents decreased to $33.1 million, while short-term investments rose to $112.8 million. The total liabilities also increased to $66.4 million, with long-term borrowings remaining stable at $35.6 million. The company continues to face challenges, including an accumulated deficit of $458.7 million, but management believes that existing cash and marketable securities will support operations over the next 12 months.

Looking ahead, SI-BONE anticipates continued revenue growth driven by increased procedure volumes and expanded market access. However, the company acknowledges potential risks, including economic downturns and changes in reimbursement policies, which could impact future performance. Management remains focused on operational efficiency and enhancing physician engagement to sustain growth in the competitive orthopedic market.